Microvascular Therapeutics is attending BIO2024, San Diego (June 3-7th). Looking forward to meeting you there! https://lnkd.in/gMcJ49Eg
Microvascular Therapeutics’ Post
More Relevant Posts
-
The 2024 Accelerating Bio-Innovation Conference is underway! Thought leaders from across the biopharma ecosystem have come together at the University of Cambridge to engage in crucial debates and discussions confronting pioneers in the world of biopharmaceuticals, bridging the realms of science, investing and innovative therapeutics. This year's conference features 50+ speakers addressing topics ranging from the challenges of developing new innovative therapies to the synergies of collaboration between academia, industry and risk capital.
To view or add a comment, sign in
-
We are very excited to have Sheff from Sheff Station for a webinar on biotech investing on April 3rd at 12pm ET! If you aren't familiar with Sheff, he is a former executive at Merck & Pfizer (combined 27 years) and has been trading biotech for 18 of those years. He brings a ton of knowledge and experience both on the science and investing sides of the table. #biotech #biotechtrading #catalysts #investinbiotech #biotech2024 #biotechoutlook #catalysts #pharma #pharmainvesting
CS Sheffield, widely known as Sheff from Sheff Station, joins us on April 3rd at 12pm ET to discuss what he looks for when analyzing biotech companies, catalysts, and to discuss the current biotech landscape. CS was a former executive at Merck and Pfizer for a combined 27 years in their oncology division and has been investing in biotech for 18 years. We are very much looking forward to the discussion! Please register via the link below: https://lnkd.in/dhZYMDVN #webinar #biotech #tradingbiotech #biotechinvesting #pharma #betherewhenithappens #catalysts
To view or add a comment, sign in
-
🔬 Reflecting on a tough 2023 & Eagerly Awaiting a Bright 2024 in Biotech! 💪🧬 2023 posed challenges for biotech with 27 closures— a stark rise from 7 in 2022. Flagship Pioneering's Rubius Therapeutics, Tessa Therapeutics Ltd, Cyteir Therapeutics, Antios Therapeutics, and Sorrento Therapeutics, Inc. faced unique hurdles, demonstrating the industry's demand for resilience. Despite closures, the biotech community showcased adaptability. Fundraising got tougher, but Pharma and biotech deals rose by 35% in 2023. 2024 brings hope with collaborations like RayzeBio-Bristol Myers Squibb and the $43B Seagen-Pfizer partnership still taking place towards the back end of the year. Will JPM Conference be the catalyst for VCs and big pharma in 2024? A lot of people seem to think so! 😁 #Biotech #Innovation #2023Reflections #2024Outlook #JPMConference #ResilienceInBiotech #JPM
To view or add a comment, sign in
-
CS Sheffield, widely known as Sheff from Sheff Station, joins us on April 3rd at 12pm ET to discuss what he looks for when analyzing biotech companies, catalysts, and to discuss the current biotech landscape. CS was a former executive at Merck and Pfizer for a combined 27 years in their oncology division and has been investing in biotech for 18 years. We are very much looking forward to the discussion! Please register via the link below: https://lnkd.in/dhZYMDVN #webinar #biotech #tradingbiotech #biotechinvesting #pharma #betherewhenithappens #catalysts
To view or add a comment, sign in
-
Lykos Therapeutics Launches With $100 Million For MDMA Treatments The Multidisciplinary Association for Psychedelic Studies (MAPS) has officially launched Lykos Therapeutics (formerly MAPS PBC) as a for profit biotechnology company to advance MDMA assisted therapies. For decades, MAPS has been leading the psychedelic renaissance through their scientific research and advocacy efforts. The pivotal launch of Lykos marks a potential turning point in the future of commercializing MDMA assisted therapies. What's happening, why it matters, and more: https://lnkd.in/e-xZiDMM Featured | cc: Rick Doblin, Michael Mullette, William Stewart, Brom Rector, CFA, Henry Elkus, Colin Whelan, Matt Saunders, Kevin Yorn #psychedelics #biotech
To view or add a comment, sign in
-
Conference Marketing Manager at Cambridge Innovation Institute | Bioprocessing | Lithium Mining | Drug Discovery | Immunogenicity | Immuno-oncology | Biopharma | Greater Boston Area
Optimized Molecules for Optimized Profiles: An AI-Driven Platform for Small Molecule Drug Discovery with Fred Manby from Iambic Therapeutics. Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Our platform enables us to widely explore chemical space, while also sampling a wide range of target product profiles. We have demonstrated our platform on initial programs, with our first scheduled for clinical entry just two years after launch. https://lnkd.in/eDBzUurr Save $150 with Discount code SPK150. #drugdiscoverychemistry
To view or add a comment, sign in
-
🌴💸 A tropical-themed Financial Friday update for you and I can only apologise for my terrible taste in clothing, luckily the positive investment rounds this week should distract you from that (alternatively just listen to the audio!) A comprehensive overview is in my video but a brief rundown of the funding this week is below: 💰 Zenas BioPharma - $200 million series C 💵 Bluejay Therapeutics - $182 million series C 🤑 Attovia Therapeutics - $105 million series B 💲 Aardvark Therapeutics - $85 million series C 💳 Latus Bio - $54 million launch #financialfriday #biotechinvestment #vcfunding
To view or add a comment, sign in
-
Navigating the complexities of cell-based bioassays (CBBAs) is key to driving success in the development of advanced therapeutics. In this webinar, Jung-Hua YEH, PhD, Principal Scientist, and Reginald Clayton, PhD, Head of Biosafety and Deputy Site Head, will delve into: ✅ Method selection for different modalities, with a focus on potency ✅ Key considerations and common pitfalls in assay development ✅ A case study on potency assays for antibody-drug conjugates ✅ The importance of a two-way partnership to ensure efficiency and program success Don't miss this opportunity to learn from industry experts and keep your drug development programs on track. 📅 Register now: https://lnkd.in/eyM9dFZe #cbba #cellbasedbioassays #bioassays #drugdevelopment #celltherapies #genetherapies #atmps
To view or add a comment, sign in
-
#DYK: ~75% of disease-causing targets are located inside cells and most are still considered inaccessible? We believe we have discovered the solution to the fundamental challenges of intracellular therapeutics. Our proprietary EEV™ platform is designed to engage targets previously considered inaccessible and undruggable and has the potential to translate into substantial improvements in efficacy, safety and tolerability of future medicines. Learn more about our EEV™-therapeutics: https://lnkd.in/dcFuBP5F #Biotech #Oligonucleotides #EndosomalEscape
To view or add a comment, sign in
-
We are very grateful for the support from the European Commission - European Innovation Council and SMEs Executive Agency (EISMEA) because is a huge impetus for Integra Therapeutics and our #FiCAT advanced therapies platform. Also, I am pleased to see that 21% of the companies chosen by #eicAccelerator are led by #women, which is an improvement over the previous call, although there is still room for improvement in the gender gap in #leadership positions in our sector. #EUeic #STEMWomen #WomenInBusiness #innovation #SocialImpact
Integra Therapeutics to receive up to €10.5 million from European Commission for its #FiCAT advanced therapies platform via the #eicAccelerator program. Learn more on our website: https://lnkd.in/d5FWP6By #investment #AdvancedTherapies #GeneTherapy #GeneWriting #CRISPR
To view or add a comment, sign in
362 followers